Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Reno, Oct. 02, 2017 -- Enhance Skin Products Inc. (OTCBB: EHSK), today announced that it has placed its Consolidated Financial Statements for the period to April 30, 2017 (Unaudited) on its website http://enhanceskinproducts.com/Filings.html
On December 2, 2016, the Company sold to Integumen Inc. substantially all of its assets and certain of its liabilities, and its primary asset is now 29,488,144 fully paid ordinary shares of one pence each of Integumen plc representing 17.87% of the issued and outstanding shares of Integumen plc. After the sale, the Company has not engaged in any business activities except to the extent necessary to preserve the value of its assets, transfer its assets and know-how, and shall in due course wind up its business affairs and give effect to the dissolution of the Company in accordance with its previously disclosed plan of reorganization, liquidation and dissolution.
As at April 30, 2017 the Company has a working capital deficit of $118,450 (2016: $995,024) and accumulated deficit of $3,002,795 (2016: $3,089,331). The Company’s primary assets as at April 30, 2017, are 29,488,144 Ordinary Shares in Integumen Limited. A day one impairment loss of $2,179,832 had been recognized for accounting and financial reporting purposes due to the fact that Integument Ltd was a newly established entity, was in the process of listing on the AIM market, did not have any history of any private placement and consequently, no valuation could have readily been ascertained. As at April 5, 2017, Integumen Ltd was established in the AIM market. As of April 30, 2017, the fair value of the 29,488,144 Integumen Ltd Ordinary Share was $1,295,132 based on the share price of 3.3918 pence ($0.04392) per share in the AIM market.
The foregoing statements are summary and reference should be made to the full Consolidated Financial Statements on the Company’s website.
Interested parties can follow the activities of Integumen plc. quoted on the AIM market of the London Stock Exchange via its website www.integumenplc.com
Contact Info
Enhance Skin Products Inc. 50 West Liberty Street, Suite 880, Reno, Nevada 89501 www.visibleyouth.com Tel: 416-306-2493
